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Summary 
CD31 is a 130-kD glycoprotein of the immunoglobulin (Ig) superfamily expressed on the sur- 
rice of endothelial cells, platelets, and several leukocyte subsets.  Previous reports indicated that 
CD31  can  mediate  intercellular adhesion via both  homophilic  and  heterophilic interaction 
mechanisms.  Using a soluble recombinant CD31-Ig fusion protein (CD31  receptor globulin 
[Rg]), we demonstrate here that human CD31- T  lymphocytes and CD4+CD31-  T  cell clones 
express a  heterophilic CD31  ligand  that is  upregulated  18  h  after activation.  Interaction of 
CD31Kg with CD31- T  helper cell (Th) clones was divalent cation independent but could be 
blocked by heparin, thus indicating that the CD31  counterreceptor on T  cells can be distin- 
guished from the ligands identified on other cell types. Moreover, a single chain protein of 120 
kD was precipitated by CD31Rg from the lysates of CD31- Th clones. CD31Rg completely 
downregulated the proliferative response and cytokine production (interleukin-4, interferon-% 
and tumor necrosis factor-o  0  of CD31-  Th clones when the cells were maximally stimulated 
via immobilized CD3  monoclonal antibody. These results suggest that interaction of CD31 
with a heterophilic counterreceptor on T lymphocytes can interfere with a positive regulatory 
pathway of T  cell activation, or directly signal T  cells to downregulate immune function. 
R 
egulation of the various functions of immune cells re- 
quires the coordinate action of soluble as well as sur- 
face-bound  molecular mediators.  The  interaction  of cell 
surface adhesion molecules with  their cognate ligands  on 
adjacent  cells  or  components  of the  extracellular matrix 
thereby facilitates  the  correct juxtapositioning of cells  in- 
volved  in  communication  with  one  another.  Simulta- 
neously,  engagement  of these  surface glycoproteins often 
results in transduction of cellular signals that direct specific 
effector functions. 
One recently characterized member of the Ig superfam- 
ily of cell surface proteins,  CD31,  also  known as platelet- 
endothelial cell adhesion molecule 1 (PECAM-1), has been 
proposed to function as such a cell adhesion molecule (1). 
CD31  is a  130-kD glycoprotein expressed on a variety of 
cell  types  of the  vascular  compartment,  i.e.,  endothelial 
cells, platelets, monocytes, and granulocytes (2-4). Within 
the population ofT lymphocytes, CD31  is expressed on a 
subset  of cells  that  is  predominantly  associated  with  the 
CD8+CD45RA §  phenotype  (5).  Molecular  cloning  and 
analysis of the predicted protein sequence revealed that the 
extracellular domain  of CD31  consists  of six  C2-type  Ig 
homology repeats  with  structural  similarity to  Fc~/P,. and 
adhesion molecules such as carcinoembryonic antigen and 
neuronal cell adhesion molecule (3, 4, 6). 
Although  the  full  range  of physiological  functions  of 
CD31  has not been established as yet, a number of lines of 
evidence suggest that it participates in cell-cell interaction 
events.  On  endothelial cells,  CD31  is  predominantly se- 
questered at sites of intercellular contact (7),  and mouse L 
cells transfected with CD31  cDNA aggregate in a CD31- 
dependent manner (8, 9). The mechanism whereby CD31 
mediates  cellular adhesion appears  to be  complex;  CD31 
has been demonstrated to bind to CD31 in homophilic in- 
teractions, as well as to participate in heterophilic interac- 
tions involving glycosaminoglycans (GAGs) 1 on the surface 
of adjacent  cells  (8-11).  In  addition  to  its  mere adhesive 
function, CD31 is considered to control dynamic processes 
such as cell activation and migration.  Coligation of CD31 
and Fc~/Rs on monocytes has been shown to induce oxida- 
tive  responses  and  release  of inflammatory  cytokines  (4, 
12).  On T  lymphocytes and myeloid cell types, ligation of 
CD31  by mAbs  upregulates  the  adhesive functions of [31 
and [32 integrins, respectively (13,  14). Abs to CD31 inter- 
fere with the transendothelial migration of neutrophils and 
monocytes, both in vitro and in vivo (15-18),  indicating 
1Abbreviations used in this paper: GAG, glycosaminoglycan;  Kg, receptor 
globulin; RT, reverse  transcriptase; T-CD31L,  T cell CD31 ligand. 
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cytes to sites of inflammation. 
Recent  evidence  also suggests that  CD31  expressed on 
the surface ofleukocytes may directly participate in the de- 
velopment of T  cell-mediated immune  responses. Within 
the population of human CD4 + T  lymphocytes, CD31  ex- 
pression appears to  differentiate between  two  functionally 
distinct subsets (19). CD4+CD31 + cells have been reported 
to exert suppressor inducer activity for B  cell IgG synthesis, 
whereas the majority of helper activity for IgG production 
by B  cells was found within the CD4+CD31-  population. 
Furthermore,  a  CD31  mAb was  able to block T  cell sup- 
pressor function in a B  cell IgG synthesis system (19),  and 
recently a peptide derived from the sixth Ig-hke domain of 
CD31  was  found  to  inhibit MLRs  (20).  Considering the 
restricted expression  of CD31  on  distinct  T  lymphocyte 
subsets,  we  supposed that  these  functional effects may be 
related to a heterophilic interaction of CD31  expressed on 
T  cells and/or accessory cells with the surface ofCD31-  T 
lymphocytes. 
To  characterize this putative heterophilic counterrecep- 
tor for CD31  on human T  lymphocytes, we constructed a 
soluble  recombinant  CD31  receptor globulin  (CD31Rg) 
consisting of the entire extracellular part of CD31 joined to 
the  constant  region of human  IgG1.  We  provide pheno- 
typical, biochemical, and functional evidence that activated 
human  T  lymphocytes and  T  cell clones  express  a  novel 
heterophilic  ligand  for  CD31,  which  is  involved  in  the 
downregulation of Th cell responses after antigen receptor/ 
CD3 triggering. 
Materials and Methods 
Abs.  Mouse mAb 7E4 (IgG2a) to CD31  (4) and 4H1-A7 to 
canine adenovirus 2  (IgG2a control)  were prepared by Dr.  O. 
Majdic  at  our  Institute.  mAbs MEM-57  (lgG2a)  to  CD3  and 
AFP-01 to ~x-fetoprotein (IgG1 control) were kindly provided by 
Dr. V. Horejsi (Institute of Molecular Genetics, Academy of Sci- 
ences  of the  Czech  Republic,  Prague,  Czech Republic).  mAb 
5E6  (IgG1) to  CD31  was obtained from The  4th  International 
Workshop on Human Leukocyte Differentiation Antigens. Hu- 
man IgG1 was purchased from Sigma Chemical Co.  (St.  Louis, 
MO). mAbs OKT3 to CD3 and anti-Leu28 to CD28 were ob- 
tained from  Ortho  Pharmaceuticals  (1karitan,  NJ)  and  Becton 
Dickinson & Co. (Mountain View, CA), respectively. 
Construction and Expression of Soluble Recombinant Rgs.  A CDM8- 
derived lgG1 expression plasmid encoding CD2Rg,  constructed 
essentially as described (21),  was kindly provided by Dr. B. Seed 
(Massachusetts  General  Hospital,  Boston,  MA).  CD31Rg  and 
M6R.g were constructed in the IgG1 expression plasmid by re- 
placing the extracellular domain sequences of CD2.  The cDNA 
sequences encoding the entire extracellular regions of CD31 and 
M6 were amplified by PCR  using the CDM8-derived plasmids 
TRMy005, containing the CD31 cDNA as insert (4), and H34, en- 
coding  the  M6  antigen  (22)  as  templates.  An  oligonucleotide 
complementary to the T7 promoter in the eukaryotic expression 
vector CDM8 was selected as universal forward primer. The reverse 
primers were designed to allow fusion of the extracellular domains 
to the human IgG1 artificial splice donor sequences in the IgG1 
expression plasmid. The sequence of the reverse primer used for 
CD31  amplification,  containing  a  BgllI  site,  was  5'-CTCGAG 
ATCTTTCTTCCATGGGGCAAGAATGACTCTGAC-3';  that 
for M6, containing a BamHI site, was 5'-CCAGAGGGGATC- 
CACGTGGCTGCGCACGCGGAGCGTGATGAT-3'. The PCR 
products  were  subcloned  into  the  pGEM-T  vector  (Promega 
Corp., Madison, WI) and verified by DNA sequence analysis. Af- 
ter digestion of the CD31  subclone with XhoI and BgllI (partial 
cleavage performed because of a second XhoI site in the CD31 
cDNA), and of the M6 subclone with XhoI and BamHI, the ex- 
tracellular domain fragments were inserted into XhoI- and BamHl- 
digested IgG1 expression plasmids. 
For production of the chimeric molecules, the expression plas- 
mids were cotransfected with a selectable marker plasmid, pSV2- 
dhfr (23) into dihydrofolate reductase-deficient CHO cells (CHO 
dhfr-)  according to  Chen  and  Okayama  (24).  Supematants  of 
transformed  colonies were  assayed  for  the  presence  of human 
IgG1  Fc fragments  by ELISA using sheep  anti-human  Ig Abs 
(Boehringer Mannheim  Co.,  Mannheim,  Germany)  as  capture 
Abs,  and  alkaline  phosphatase-conjugated  goat  F(ab')2  anti- 
human IgG Abs (Sigma Chemical Co.) as detection Abs. Positive 
transformants were subcloned by limiting dilution and then pas- 
saged in increasing concentrations of methotrexate at a final level 
ofl p.M. Transformants  producing high levels of  the chimeric mole- 
cules were expanded in serum-free Ultraculture medium (Whit- 
taker Bioproducts, Walkersville, MD), and the recombinant pro- 
teins  purified  from  the  supernatants  using  a  protein  A-CR 
column (BioProcessing Ltd., Consett, UK). SDS-PAGE analysis 
of the purified molecules revealed bands of expected size under 
both reducing and nonreducing conditions. 
Cells and Cell La'nes.  Human T cell lines were cultured in RPMI 
1640  medium supplemented with 10% FCS and 2 mM r-gluta- 
mine.  Human  PBMCs  were  isolated from  peripheral blood of 
healthy donors using FicoU-Hypaque (Pharmacia, Uppsala, Swe- 
den) density gradient centrifugation. 
Human CD4+CD31 -  T  cell clones, TC-1, TC-2, and TC-3, 
were  established and  maintained  as  described  elsewhere  (25). 
Briefly,  CD4+CD45RO -  T  cells  from  healthy  donors  were 
cloned in a feeder cell-free system in 96-well round-bottom mi- 
crotiter plates with  OKT3-coated sheep  anti-mouse IgG mag- 
netic Dynabeads M-450 (2-5 ￿  104/well; Dynal, Oslo, Norway), 
soluble anti-Leu28  (0.5  p,g/ml), and human  rlL-lot, rlL-2 and 
rlL-6 (100  U/ml each; Sandoz Research Institute, Vienna, Aus- 
tria) in RPMI  1640  medium supplemented with 5% pooled hu- 
man serum and 2 mM L-glutamine. Clones were further propa- 
gated  by  a  14-d  restimulation  procedure  using  the  stimuli 
described above. 3-4 d after each restimulation, the cultures were 
split and subcultured in the presence of human rlL-2 (50 U/ml) 
and anti-Leu28 (0.25  I,  zg/ml). The three clones with CD31-neg- 
ative phenotype were randomly selected from different donors. 
All cells were maintained in a humidified atmosphere of 5% CO2 
at 37~ 
Stimulation of T Cells and T Cell Clones.  PHA-activated T  cells 
were prepared by culturing PBMCs in RPMI 1640 medium sup- 
plemented with 10% FCS and 2 mM L-glutamine in the presence 
of 0.01  U/ml PHA (Wellcome, Beckenham,  UK)  for the times 
indicated. 
Cloned T cells were collected on day 14 after the last restimu- 
lation with OKT3-coated beads. After removal of residual OKT3 
beads, cells were activated at a concentration ofl-5 ￿  10  4 cells/well 
in RPMI 1640 medium supplemented with 10% FCS and 2 mM 
L-ghitamine in 96-well round-bottom plates for the times indi- 
cated. For stimulation via CD3, plates were precoated with OKT3 
mAb at a concentration of 1 txg/ml in PBS  (50  p,1/well)  over- 
42  CD31  Ligand on T Cells night at 4~  To assess the influence of Rgs on proliferation and 
cytokine production, CD31Kg, M6Kg, or human IgG1 was co- 
immobilized on the plates at 10 ~g/ml in PBS, unless otherwise 
indicated.  After incubation, plates were washed three times with 
PBS and blocked for 30 min at 37~  with R.PMI 1640 medium 
supplemented  with 10% FCS. Soluble factors, i.e., PMA (60 ng/ml; 
Sigma Chemical Co.) plus calcium ionophore (ionomycin, 1 nM; 
Sigma Chemical Co.) or human rlL-2 (100 U/ml), were added 
to a final volume of 200 ~1 at the initiation of culture. 
Immunofluorescence Analysis.  Cells were incubated with mAbs 
or Kgs (20 p~g/rnl) in PBS containing 1% BSA and 0.02% NaN  3 
for 60 min at 4~  After washing,  cells were stained for a further 
30 rain at  4~  with the second step  reagent,  FITC-conjugated 
sheep F(ab')2 anti-mouse IgG +  IgM Abs (An der Grub, Vienna, 
Austria)  or PE-conjugated donkey F(ab')2 anti-human IgG Abs 
(Jackson ImmunoResearch Laboratories, West Grove, PA), respec- 
tively. To prevent nonspecific binding ofmAbs or Rgs to Fc recep- 
tors, the cells were preincubated for 30 rain at 4~  with 4 mg/ml 
of human Ig or with 5% normal rabbit and 5% normal goat se- 
rum, respectively.  To determine divalent cation and heparin sen- 
sitivity  of Rg binding to T  cell clones,  EDTA (10 raM) or hep- 
arin  (sodium  salt, 12.5-50  ~g/ml;  Sigma  Chemical  Co.)  was 
included during all incubation steps of the staining protocol. Fluo- 
rescence was analyzed on a FACScan  |  flow cytometer (Becton 
Dickinson & Co.); dead cells were excluded from the analysis by 
DNA staining  with ethidium bromide. Viability  of the cells after 
staining was typically >90% under all conditions tested. Cytofluo- 
rometric analysis of the T  lymphocyte fraction of PBMCs was 
performed by electronically  gating CD3 + cells. 
Reverse Transcriptase-PCR.  Total RNA was isolated from Ju- 
rkat cells and  CD31-  Th  clones  by a single  step  method  (26). 
First strand  cDNA was prepared from 10 p,g total P,.NA by re- 
verse  transcription  using  200  U  Moloney-MLV  reverse  tran- 
scriptase  (RT;  GIBCO BILL,  Gaithersburg,  MD)  and 50 pmol 
oligo(dT) primer.  Aliquots of KT reactions (1/20 total volume) 
were  amplified  by  PCR  (27) using  a  thermal  cycler Perkin- 
Elmer-Cetus (Emeryville,  CA) in a 50-~1 final volume. The fol- 
lowing oligonucleotides were used to amplify CD31 cDNA: F1 
(sense) - 5'-AGTGAGGTTCTGAGGGTGAAGG-3', R1 (anti- 
sense) - 5'-TCACTCCGATGATAACCACTGC-3';  F2 (sense) - 
5'-TCTATCCTGTCAAGTAAGGTGG-3'; and R2  (antisense) 
- 5'-GGCAAGAATGACTCTGACTGTC-3'. Denaturation, an- 
nealing, and extension reactions  were carried out at 94~  for 45 s, 
55~  for 45 s, and 72~  for 30 s, respectively,  for 35 cycles. The 
relative amount of input cDNA was analyzed by an internal  con- 
trol PCR using [3-actin-specific  primers (28). Similar results were 
obtained when separate reactions were performed for the amplifi- 
cation of CD31 and ~-actin cDNAs. Identity of amplified  frag- 
ments was verified by restriction digestion. 
Labeling of Cells and Precipitation.  For solid phase immunoiso- 
lation  of cell  surface  proteins  (29),  96-well  plastic  plates  were 
coated with rabbit anti-human IgG Abs (DAKO, Glostrup, Den- 
mark)  in PBS and, after washing, with CD31Rg, M6Kg, or hu- 
man IgG1 at a concentration of 50 p,g/ml in PBS.  Cell surface 
proteins were biotinylated using NHS-LC-biotin (Pierce Europe, 
Oud-Bejerland,  The Netherlands),  as described previously (30). 
Surface-labeled  cells were solubilized  in lysis buffer containing t% 
NP-40,  50 mM  Tris-HC1,  pH 8.0,  150  mM NaC1,  10  Ixg/ml 
aprotinin, 2 wg/rnl leupeptin, and 1 mM PMSF. The lysates were 
centrifuged, precleared with human IgG1 and protein A-Sepharose 
beads,  and subjected to immunoisolation using the coated plates. 
Precipitated  proteins  were  separated  by SDS-PAGE and  trans- 
ferred  to a  nitrocellulose  membrane.  The  biotinylated  proteins 
were visualized using streptavidin-conjugated horseradish  peroxi- 
dase  and  the  enhanced  chemiluminescence  detection  system 
(Amersham International, Amersham, Bucks, UK). 
To determine heparin sensitivity of Rg precipitates,  Rg-coated 
plates were preincubated with heparin for 30 min, and heparin was 
included during immunoisolation at a concentration of 50 I.Lg/ml. 
Proliferation and Cytokine Assays.  CD31- Th clones were stim- 
ulated at a concentration of 104 cells/well as described above for 
48 and 72 h in a total volume of 200 I.fl in 96-well round-bottom 
plates.  Cellular  proliferation of triplicate  cultures  was determined 
by quantitating [3H]thymidine (1 ~Ci/well) incorporation during 
the last 18 h of culture. Cytokine secretion by T cell clones was an- 
alyzed in supernatants of  the stimulation assays after 48 h of culture. 
Concentrations of IL-4, IFN-"/, and TNF-~x were determined by 
antigen-capture ELISA, as described previously (12, 31). 
Results 
Expression of a Heterophilic  Ligand for CD31  on Activated  T 
Lymphocytes.  To  determine  whether  human  T  cells  ex- 
press a heterophilic ligand for CD31, we first examined the 
reactivity of CD31Rg with several human  T  cell hnes.  A 
comparison of the binding activities of CD31ILg and CD31 
mAbs, as assessed by indirect immunofluorescence and flow 
cytometric  analysis,  revealed  that  T  cell  lines  with  both 
CD31 + (Jurkat, Molt-4) and CD31- phenotype (HUT-78, 
HPB-ALL) specifically bound CD31Rg, but not an analo- 
gous control fusion protein  (M6Rg)  or human IgG1  (data 
not shown). Thus, this initial experiment indicated that hu- 
man T  cells  might interact with CD31Rg in a homophilic 
and/or heterophilic way. 
It has been shown that CD31  is expressed  on "-~50% of 
human peripheral  blood T  lymphocytes, and that this  bi- 
modal expression remains virtually unchanged upon cellu- 
lar  activation  (5,  19).  When  we  examined  the  ability  of 
CD31Rg to interact with freshly isolated human peripheral 
blood T  lymphocytes, both the CD31 + and CD31- subsets 
of T  lymphocytes failed to stain with CD31Rg. However, 
after  stimulation  with  PHA  in  the  presence  of accessory 
cells, 90 +  3% (n =  6) of the T  blasts specifically bound the 
chimeric protein, but showed no significant reactivity with 
M61Lg or human IgG1. CD31Rg binding reached a peak 
level as early as 18 h after activation, maintained it for a fur- 
ther 48  h,  and  declined thereafter  (Fig.  1 A).  In contrast, 
the  expression  of the  CD31  molecule,  as  determined  by 
CD31  mAb staining,  was restricted  to 61  +  4% of the  T 
lymphocytes in  their  resting  state  and  decreased  to  54  + 
2% of cells at the time point of maximal CD31Rg binding. 
CD31  expression was slightly increased at day 4  of activa- 
tion  when  CD31Rg  staining  had  returned  almost  to  the 
level of resting cells  (Fig.  1  B).  These  differential  binding 
patterns ofCD31 mAbs and CD31Kg indicate that the chi- 
meric fusion protein identifies a heterophilic  CD31  ligand 
that is expressed by at least 36% of human T  lymphocytes 
and  is  temporally  regulated  during  T  cell  activation.  We 
therefore designate this T  cell surface molecule recognized 
by CD31Rg as the T  cell CD31 ligand (T-CD31L). 
Expression  of a Heterophilic  Ligand for CD31  on Activated 
CD31-TCell  Clones.  To  characterize  T-CD31L  with- 
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Figure 2.  Expression  of a heterophilic counterreceptor for CD31 on 
activated human CD31-  T cell clones. T cell clone TC-I was restimu- 
lated via immobihzed  CD3 mAb OKT-3 plus IL-2 for the times indicated 
and then analyzed  for reactivity  with CD31Rg by indirect immunofluo- 
rescence and flow cytometry. (Open areas) Background  levels of fluores- 
cence obtained with control M6Rg. The data are representative of five 
experiments. Similar  results were obtained with T cell clones TC-2 and 
TC-3. 
Figure 1.  Reactivity of CD31Rg and CD31 mAb with activated hu- 
man peripheral blood T lymphocytes. Human PBMCs were activated 
with  PHA  (0.01 U/ml)  for  the  times indicated, and the  binding of 
CD31Rg or CD31 mAb to T cells was analyzed  by indirect irnmunofluo- 
rescence and flow cytometry. (A) Reactivity of CD31Rg (shaded area) or 
control M6Rg (open area). (B) Reactivity ofCD31 mAb 7E4 (shaded  area) 
or isotype-matched control mAb (open area). Identical staining profiles 
were obtained with CD31 mAb 5E6. The result is a representative  of six 
independent experiments. 
out any partial influence of a  putative CD31  homophilic 
interaction, we established a panel of human T  cell clones 
with  CD31-  phenotype  (see  Materials  and  Methods). 
Three clones derived from different donors (termed TC-1, 
TC-2,  and TC-3) were  chosen for all subsequent experi- 
ments. These clones were classified as CD3+CD4  + CD8- 
CD31- using indirect immunofluorescence and FACS  |  anal- 
ysis  (Becton Dickinson &  Co.; data not shown). A  kinetic 
analysis of Rg reactivity by the  clones revealed a  specific 
binding of CD31Rg that was strictly dependent on the ac- 
tivation state of the cells, as seen earlier with peripheral T 
lymphocytes.  CD31Rg binding reached peak levels  18  h 
after restimulation via immobilized CD3 mAb OKT3 and 
IL-2 (>90% positive cells) and decreased gradually 3 d after 
activation  (Fig.  2).  This  apparent  upregulation  of  a 
CD31Rg-binding molecule was independent of the stimu- 
lus  used,  since  the  same  results  were  obtained when  the 
clones were restimulated via immobilized CD3 mAb alone 
or in the presence of PMA plus calcium ionophore (data 
not shown).  However,  under all the  restimulation condi- 
tions assayed, no binding ofCD31 mAbs could be detected 
(data  not shown),  therefore  distinguishing these  clones as 
potential candidates for the study of the heterophilic inter- 
action of CD31  and T-CD31L on a homogenous CD31- 
T  cell population. 
To conclusively prove the  CD31- phenotype of the  T 
cell clones, we had to exclude the possibility that CD31Rg 
recognized an isoform or posttranslational modification vari- 
ant ofCD31 undetectable by the CD31 mAbs used. To ad- 
dress this issue, we analyzed CD31  expression at the RNA 
level using CD31-specific primers. RT-PCR analysis of  RNA 
prepared from the resting as well as the previously activated 
T  cell clones demonstrated the absence of CD31 transcripts 
in these cells, whereas CD31 mRNA was easily detected in 
the  CD31 +  T  cell line Jurkat  (Fig.  3).  These results were 
obtained whether RNA was isolated 1, 2, or 14 d after re- 
stimulation of the T  cell clones. 
Effect of Divalent  Cations and Heparin on  CD31Rg Binding 
to T  Cells.  Previous reports have shown that the CD31- 
mediated heterophilic aggregation of mouse L cells is diva- 
lent cation dependent and involves heparin or chondroitin 
sulfate residues on the surface of adjacent cells (9-11). We 
therefore investigated whether divalent cations or heparin 
could modify the binding of CD31Rg to activated CD31- 
T  cell clones. Preincubation of CD31Rg with heparin (12.5- 
50  lig/ml)  completely abolished the  binding of the  chi- 
meric construct to the clones, resembling its effect in the L 
cell  aggregation  system  (Fig.  4  A).  However,  Ca  2+  and 
Mg  2+ ions were not essential for CD31Rg binding, insofar 
as EDTA rather enhanced the mean fluorescence intensity 
of CD31Rg-stained cells by 37  +  6% (n =  3) as compared 
with divalent cation-containing  medium (Fig. 4 A). Reac- 
tivity  of a  positive  control  fusion  protein,  CD2Rg,  re- 
mained  virtually  unchanged  under  all  conditions  tested 
Figure 3.  CD31-  T cell clones express no CD31 mRNA. RT-PCR 
analysis of RNA from human CD31  T cell clones TC-1,  TC-2,  and 
TC-3 as well as the CD31  + T cell line Jurkat was performed using the 
CD31-specific oligonucleotides,  F1 and R1. The same findings  were ob- 
tained with a different  set of CD31-specific primers, F2 and R2 (see Ma- 
terials and Methods). Equal aliquots of PCR reactions were electrophore- 
sed  on a 2% agarose gel containing ethidium bromide (+). Negative 
control reactions were performed without RT (-). The relative amount of 
input cDNA was standardized  by an internal control PCR using ~-actin- 
specific primers. The expected size of the CD31 and [3-actin  PCR prod- 
ucts are 369 and 245 bp, respectively. (Lane M) A 123-bp DNA ladder as 
size standard. The data are representative  of three experiments. 
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Figure 4.  Effect  of divalent cations and heparin on CD31Rg binding 
to human CD31- T cell clone TC-1. Stimulation was performed as indi- 
cated in the legend to Fig. 2. The cells were analyzed 48 h after activation 
for reactivity with CD31Rg (A) or CD2Rg (/3) by indirect immunofluo- 
rescence and flow cytometry. Staining with lkgs was performed in PBS 
containing  either  t  mM  Ca  2+  and  1 mM  Mg  a+  (-EDTA),  10  mM 
EDTA (+EDTA),  or 12.5 I~g/ml heparin. (Open  areas)  Background levels 
of fluorescence obtained with control M6Rg. The data are representative 
of three independent experiments. 
(Fig. 4  B), demonstrating that these effects were CD31Rg 
specific. 
Immunoprecipitation  of  Cell  Surface  Protein  Binding  to 
CD31Rg.  To  characterize the molecular nature  of the T 
cell surface molecule involved in CD31Rg  binding, TC-1 
cells were  surface  biotinylated,  and  the  lysates were  sub- 
jected to precipitation with CD31Rg.  Analysis of the preci- 
pitates by SDS-PAGE showed a prominent band of ,-o120 
kD, that was selectively present in the lysates of previously 
activated, but  not  of resting TC-1  cells (Fig.  5  A, lanes  1 
and 3). This protein was identical in size under both nonre- 
ducing and reducing conditions (Fig. 5 A, lanes 3  and 3'), 
and was  not observed in precipitates of control M6P,.g or 
human  IgG1  (Fig.  5  A, lanes  4  and  4').  Affinity isolation 
experiments using T  cell clones TC-2 and TC-3, as well as 
the  CD31-  T  cell lines HUT-78  and HPB-ALL revealed 
the  same  specific  120-kD  band  (Fig.  5  B,  lanes  1-4,  and 
data not shown). Precipitation of the  120-kD protein from 
the  T  cell clones and  T  cell lines by CD31Rg  was  com- 
pletely  abolished  when  the  immunoisolation  was  per- 
formed in  the  presence  of heparin  (Fig.  5  C,  lanes  1-4). 
This  finding  supports  the  involvement  of  GAGs  in 
CD31Rg reactivity with different cell types ofT cell origin. 
CD31Rg  Inhibits  Activation  of  Human  CD31-  T  Cell 
Clones.  CD31  has been shown  to represent a  cell surface 
marker that allows CD4 § T  cells to be subdivided into those 
that exert the suppressor inducer (CD31+),  and the helper 
(CD31-) function for B  cell IgG synthesis (19). This observa- 
tion, together with our finding that expression of T-CD31L is 
restricted to T  cells at certain stages of activation, prompted 
us to examine whether T-CD31L/CD31  might represent a 
novel accessory system of T  cells. We first assessed the in- 
fluence of CD31Rg on activation-induced IL-2 production 
by the human CD31-  T  cell line HUT-78.  In the presence 
of immobilized CD3  mAb, HUT-78  cells produced mod- 
erate levels of IL-2 (32), which significantly increased upon 
costimulation with  CD28  mAb.  Addition of CD31Rg  to 
CD3-stimulated cultures did not augment  IL-2 accumula- 
tion, indicating that the fusion protein could not provide a 
costimulatory  signal  under  these  conditions.  In  contrast, 
when HUT-78  cells were stimulated maximally via immo- 
bilized CD3  plus  CD28  mAbs in  the  presence  of soluble 
CD31Rg,  a significant inhibition (~60%)  of IL-2 produc- 
tion  was  observed  as  compared  with  cultures  stimulated 
with  mAbs alone  or in  the  presence  of Rg  controls  (data 
not shown).  These experiments suggested that engagement 
of T-CD31L  by CD31Rg  may be involved in the down- 
regulation ofT  cell responses after initial activation. 
To analyze the inhibitory potential of CD31Rg  in more 
Figure 5.  Biochemical charac- 
terization of the CD31Rg-bind- 
ing protein. Precipitates obtained 
from  lysates of biotin  surface- 
labeled TC-1  cells and human T 
cell lines  were analyzed by SDS- 
PAGE under  nonreducing  con- 
ditions. Atier transfer to a nitrocel- 
lulose membrane,  biotin-labeled 
proteins were visuahzed using a 
streptavidin-biotinylated  horse- 
radish peroxidase  complex  and 
enhanced chemiluminescence  de- 
tection system. (A) Immunopre- 
cipitation  with  resting  (lanes 1 
and 2) and previously activated (lanes 3 and 4) TC-1 cells using CD31Rg (lanes 1 and 3) or control M6Rg (lanes 2 and 4). These samples  were also ana- 
lyzed under reducing conditions (lanes 1  '-4'). (B) Precipitation with HUT-78 (lanes 1 and 2) and HPB-ALL cells (lanes 3 and 4) using CD31Rg (lanes 
I and 3) and control M6Rg (lanes 2 and 4). (C) Precipitates obtained from activated TC-1 cells using CD31P, g (lane 1) and control M6Rg (lane 4) in the 
absence, or CD31Rg (lane 2) and M6Rg (lane 3) in the presence of 50 I.tg/ml heparin. Biotinylated molecular mass standards are indicated in kilodahons. 
The results are representative of three independent experiments for A, B, and C, respectively. 
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cytokine  production  of the  CD4+CD31 -  T  cell  clones 
TC-1, TC-2, and TC-3. The clones were restimulated via 
immobilized  CD3  mAb  in  the  presence  or  absence  of 
CD31Rg, and [3H]thymidine incorporation was determined 
during the last  18  h  of 48- and 72-h cultures.  The results 
obtained are shown in Fig. 6 A  with clone TC-1  as a rep- 
resentative.  The proliferative  response  of the  cells was re- 
duced by 75 +  2% (n =  4) when CD31P,  g (10 beg/m]) was 
coimmobilized on the  plates,  whereas  no inhibitory effect 
was  observed after coimmobilization  of control M6P, g  or 
human IgG1. Similar results were obtained when CD31Rg 
was  added in  soluble  form,  although the  inhibitory  effect 
was less pronounced  (data not shown).  A  titration  experi- 
ment revealed a significant inhibition of [3H]thymidine in- 
corporation  with  CD31P,.g immobilized  at  5  beg/m],  and 
an almost complete abrogation of the proliferative response 
at  20  beg/m]  (Fig.  6  B).  However,  coimmobilization  of 
CD31Rg had no influence on proliferation when we added 
IL-2 to  these  cultures.  Furthermore,  although  TC-1  cells 
proliferated only modestly upon stimulation with PMA and 
calcium ionophore, this response could also not be blocked 
by immobilized  CD31Rg  (Fig.  6  A).  Addition  of soluble 
CD28 mAb to CD3-stimulated cultures neither augmented 
the CD3-induced response nor reversed the inhibitory ef- 
fect of CD31Rg (data not shown). This apparent unrespon- 
siveness  to  CD28  stimulation  might  result  from the  pro- 
longed culture of the T  cell clones in the presence of CD28 
mAbs (see Materials and Methods),  resulting in a desensiti- 
zation of their CD28-signaling pathway (33). 
Next,  we evaluated the profile of cytokine release  from 
the  T  clones  in  response  to  immobilized  CD3  mAb  or 
PMA  plus  calcium  ionophore.  All  three  clones  secreted 
high levels of IL-4, low levels of IFN-y, and no or mini- 
mum  amounts  of IL-2,  a  pattern  that  resembles  a  Th2/0 
cell  type  (34).  As  in  the  proliferation  assay,  addition  of 
CD28 mAb to CD3-stimulated  cultures had no significant 
effect. 
To assess the influence of CD31Rg on the cytokine se- 
cretion capacity of the clones, supernatants were collected 
48  h  after restimulation  and  analyzed for the  presence  of 
IL-4, IFN-% and TNF-0~. Immobilized CD31Rg (10 beg/ml) 
specifically inhibited the release of all three cytokines when 
the  cells were  activated via immobilized  CD3  mAb.  IL-4 
secretion was reduced by 91  +  2% (n =  4), whereas IFN-y 
and TNF-ot release were decreased by 92  +  7% and 88  +- 
7%,  respectively  (Fig.  7).  The inhibition  was dose depen- 
dent,  and  complete  downregulation  of cytokine  produc- 
tion  to  the  basal  levels  of unstimulated  cultures  was  ob- 
served when CD31Rg was immobilized at 20 beg/ml (data 
not shown). In contrast to its ability to completely abrogate 
the inhibitory effect of CD31Rg in the proliferation assays, 
IL-2 could only partially reverse the inhibition  of cytokine 
release  (Fig. 7).  Thus,  the inhibitory effect of CD31Rg on 
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Figure 6.  Effect  of CD31R.g on the proliferative response of  human CD4+CD31- T cell clone TC-1. (A) Cells (10 4) were cultured in the presence of 
CD3/nAb OKT3 (1 btg/rnl) coimmobilized  with CD31Rg or a control Rg (10/.tg/ml) alone or in combination  with IL-2 (100 U/ml). In addition, TC-1 
cells were also restimulated with PMA (0.1 nM) plus the calcium ionophore ionomycin (1 nM) in the presence of  immobilized CD31Rg or control tkg. 
The data presented are representative of four independent experiments. (B) TC-1 cells were cultured in the presence of CD3 mAb OKT3 (1 Izg/ml) 
coimmobilized with CD31R.g or control Ikg at the concentrations  indicated￿9  Proliferation was determined at 48 h. Results are expressed as mean cpm -+ 
SE of triplicate determinations. 
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as mean +  SE of duplicate determinations. Note that different  scales are used for each of the three cytokines. The results are representative of four inde- 
pendent experiments. The same findings  were obtained in experiments performed with the clones TC-2 and TC-3. 
cytokine release seems to be not just a consequence of de- 
creased proliferation rate and reduced cell number. Similar 
to  the  proliferation assays, restimulation  of TC-1  clones 
with PMA and calcium ionophore completely bypassed the 
blocking effect of CD31R.g (Fig. 7). 
Discussion 
In recent years, several reports have  demonstrated that 
CD31 can be considered as an adhesion molecule with both 
homophilic and heterophilic binding properties (9-11, 35, 
36).  The interaction mechanisms  of leukocyte CD31,  in 
particular,  have been studied primarily with regard to the 
process oftransendothelial migration (15, 18, 37, 38); how- 
ever, very little is known about the molecular nature of a 
putative heterophilic counterreceptor(s) of CD31  on leu- 
kocytes, and its function in their internal communication. 
Using a soluble CD31R.g containing the entire extracelluar 
domain of CD31, we demonstrate here that activated hu- 
man T cells express a heterophilic CD31 counterligand with 
potential accessory function in T  lymphocyte responses. 
At  18  h  after activation of T  lymphocytes, when not 
>54%  of T  cells  expressed CD31,  a ligand  for CD31Rg 
was expressed on the surface of almost all of these cells, and 
completely downregulated 4-5 d after activation. The het- 
erophilic nature of the interaction of CD31Rg with human 
T  cells  was  corroborated  by  the  generation  of human 
CD31-  T  cell clones that also bound CD31R.g upon acti- 
vation,  but  did  not  display  either  reactivity with  CD31 
mAbs, or expression ofCD31 mR.NA. 
We designated this heterophilic CD31  ligand expressed 
by activated T  cells  T-CD31L because its  features distin- 
guish it from all other heterophilic ligands  so far identified. 
First,  in the mouse L  cell aggregation assay, CD31-medi- 
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ated heterophilic adhesion has been shown to depend on 
divalent cations and to be perturbed by restricted classes of 
GAGs, such as heparin and heparan sulfate.  Accordingly, it 
has  been  proposed that  CD31,  via  a  consensus  heparin- 
binding motif in the second Ig-like domain, could bind to 
GAGs in the extracellular matrix, or to a GAG-containing 
counterreceptor on  the  surface  of adjacent  cells  (9,  10). 
The binding properties of CD31kg to T-CD31L only par- 
tially concur with these observations.  Heparin specifically 
abolished the  reactivity of CD31P,.g with  CD31-  T  cell 
lines and activated T  cell clones, yet the interaction did not 
require the presence of Ca  2+  and Mg  2+  ions. By contrast, 
removal of divalent cations reduced the reactivity of  CD31Rg 
with  human  CD31-  fibroblastoid  cell  lines  by  30-70% 
(data  not  shown).  Second,  while  this  manuscript  was  in 
preparation,  otv[33 integrin  (CD51/CD61  complex)  has 
been reported to serve as a ligand for a truncated recombi- 
nant form of CD31 containing the three NH2-terminal Ig- 
like  domains  of  the  molecule  (39).  Contrary  to  the 
CD31kg-T-CD31L interaction, binding of CD31 to  0t.v[~  3 
has been demonstrated to be divalent cation dependent but 
insensitive to heparin. The difference between the two CD31 
counterreceptors,  T-CD31L  and  O/v[~  3  integrin,  is  further 
emphasized by our biochemical studies:  CD31R.g precipi- 
tated a single chain protein of 120 kD from surface-labeled, 
activated Th clones, which could specifically be displaced 
by addition ofheparin (Fig. 5). Moreover, our T cell clones 
showed  no  significant  reactivity with  CD51  and  CD61 
mAbs (data not shown). 
Taken together, these observations suggest that T-CD31L 
represents an additional counterreceptor for CD31, which 
might be associated with a similar GAG-containing carbo- 
hydrate structure as the ligand described in the L cell sys- 
tem. Thus, similar to other members of the Ig superfamily, CD31  seems to be capable of interacting with a multiplicity 
of counterligands  on different cell types. Alternative splic- 
ing of the cytoplasmic domain of CD31  has been reported 
to result in a change of the configuration of the extracellu- 
lar,  hgand-binding  domain  of the  molecule  (40--42),  and 
intracellular phosphorylation of CD31  might as well mod- 
ulate its adhesive properties (43).  It is conceivable to specu- 
late  therefore,  that  different  cytoplasmic variant  forms of 
CD31  each  interact  preferentially  with  CD31  in  a  ho- 
mophilic fashion or with one of the heterophilic counterli- 
gands described so far, thereby offering the opportunity to 
regulate specific cell-cell interactions. 
The  diversity  of,  possibly  cell  type-specific,  counter- 
receptors  for  CD31  might  also  account  for the  different 
physiological  functions  that  have  been  attributed  to  this 
molecule  (see  Introduction).  The  binding  of  CD31  to 
%[33  ,  for  example,  has  been  implicated  in  leukocyte- 
endothelial  interaction,  indicating  an  involvement of this 
adhesion  pair  in  the  transendothelial  migration  process 
(39).  On  the  other  hand,  we  here provide  evidence  that 
T-CD31L represents a novel accessory molecule ofT lym- 
phocytes  involved  in  the  downregulation  of effector Th 
cell responses.  Activation of human  CD31-  Th clones  in 
the  presence  of cross-linked  or  soluble  CD31R.g  com- 
pletely abrogated the proliferative response and production 
of effector cytokines (IL-4, IFN-y, and TNF-Ix) when the 
cells were maximally stimulated with a CD3 mAb. CD31Rg 
seems to interfere primarily with  the  autocrine  and  para- 
crine cytokine production of Th cells, since exogenous IL-2 
could reverse the inhibitory effect of CD31P,.g on prolifer- 
ation, but only partially restore the cytokine-producing ca- 
pacity of the clones (compare Figs.  6 and 7).  Therefore, the 
inhibitory effect of CD31R.g on the proliferative response 
might be due merely to the downmodulation of autocrine 
IL-2  production.  A  complete  reversal  of the  CD31Rg- 
mediated inhibition could only be accomplished when the 
TCR signaling was bypassed by stimulation with PMA and 
calcium  ionophore,  suggesting  that  CD31Rg  interferes 
with a step upstream of signal-induced calcium influx and 
protein kinase C  activation. 
Although our results do not rule out the possibility that 
CD311Kg exerts a different,  maybe opposite effect on the 
responses of naive/memory T  cells,  preliminary data  sug- 
gest  that  the  fusion  protein  can  also  inhibit  proliferation 
and cytokine production of freshly isolated human T  lym- 
phocytes (data not shown).  Furthermore,  the blocking ef- 
fect of CD311Kg observed in  our functional assays is sup- 
ported  by  a  recent  report  by  Zehnder  et  al.  (20),  who 
demonstrated that a peptide derived from CD31  could spe- 
cifically inhibit T  lymphocyte responses in primary MLRs. 
However, whereas a direct adhesive mechanism involving 
CD31  has not been established in these studies, our pheno- 
typical and biochemical results are consistent with a hetero- 
philic interaction of CD31Ikg with Th cells that may result 
in the transmission of a negative signal inside the cell.  Al- 
ternatively,  the  binding  of CD31Rg  might upregulate  or 
activate a  negative regulatory molecule  on  the  surface  of 
the T  clones, which then interacts with a putative counter- 
receptor  on  apposing T  cells.  A  third  explanation  of the 
data presented here is that  CD31Rg  could  compete with 
the interaction of a surface protein with a soluble factor or 
a  counterligand  on  adjacent  cells,  thereby preventing the 
transduction of a positive signal. 
Although  a  number of cell surface receptors are  impli- 
cated in the costimulation or augmentation oft  cell activa- 
tion, molecules whose function is to dampen or downregu- 
late T  cell reactivity have not been extensively investigated. 
The most well-characterized accessory molecule ofT lym- 
phocytes with  a  supposed  negative  regulatory function  is 
CTLA-4,  a  cell surface protein  of the  Ig superfamily in- 
duced  during  T  cell activation  (44).  Anti-CTLA-4 m_Abs 
can block the proliferative response and cytokine produc- 
tion of T  lymphocytes (45,  46) and trigger antigen-specific 
clonal deletion of previously activated T  cells (47).  The in- 
hibition of Th cell responses by CD31R.g is reminiscent of 
the downregulatory effect of CTLA-4 mAbs. However, un- 
like CTLA-4 engagement by mAbs, interaction of CD31t<g 
with T-CD31L does not appear to result in enhanced apop- 
tosis of previously activated Th clones, as assessed by pro- 
pidium iodide staining and FACS |  analysis at different time 
points after activation (data not shown).  In analogy to the 
multiplicity  of positive  regulatory costimulators  of T  cell 
activation  (48,  49),  it  might  be hypothesized  that  several 
functionally  different  cell  surface  molecules  participate  in 
the  termination  of a  prevailing  T  cell  response,  thereby 
regulating the  strength  and  specifics of the  particular im- 
mune reaction. Alternatively, the CD31/T-CD31L adhesion 
pair might play a more specialized role in the physiology of 
CD31-  T  lymphocytes.  Since  CD31  has  been  demon- 
strated to define cells of  the suppressor lineage (19), its hetero- 
philic interaction with T-CD31L on the surface  of CD31- 
Th cells might result directly in the generation of suppressor 
signals.  The elucidation of the definite role of T-CD31L in 
T  cell immunity must await the molecular cloning of this 
molecule and a more detailed analysis  of its function in the 
responses ofCD31 + and CD31  T  lymphocytes. 
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